Granted Patent B2

US 12,318,414 · App. 18/620,483 · Granted Jun 3, 2025

Inventors: Sheri Simmons (Brookline, MA); Joseph E. Kovarik (Englewood, CO)

Assignee: Seed Health, Inc.

A61K35/741A61K31/58A61K31/715A61K35/74A61K35/745A61K35/747A61K38/1709A61K38/1758C12N1/20A61K2035/11A61K2035/115

Abstract

Claims (26)

1. A method for modifying an individual's gut-brain axis to provide neurocognitive protection, comprising, providing an individual human being with a population of beneficial bacteria selected from the group consisting of at least two bacteria that comprises bacteria selected from the group consisting of Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp., Lactobacillus paracasei, Nitrosomonas eutropha , Blautia, Lactobacillus plantarum and Veillonella , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of butyrate by the beneficial bacteria, wherein the beneficial bacteria are encapsulated in a frangible enclosure, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual.

2. The method as set forth in claim 1 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

3. The method as set forth in claim 1 , further comprising inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.

4. The method as set forth in claim 1 , further comprising reducing a number of bacteria in the gut of the individual selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

5. The method as set forth in claim 1 , wherein the population of beneficial bacteria include bacteria that have been modified using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system.

6. The method as set forth in claim 1 , further comprising increasing the populations of at least two of the following in the individual's gut microbiome: Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella.

7. The method as set forth in claim 1 , wherein said beneficial bacteria generate tryptophan metabolites that act as aryl hydrocarbon receptor (AHR) agonists.

8. The method as set forth in claim 1 , wherein said beneficial bacteria produce tryptophan metabolites selected from the group consisting of indole-3-aldehyde, indole-3-ethanol, indole-3-pyruvate, and indole-3-acetic acid.

9. The method as set forth in claim 1 , wherein said beneficial bacteria further comprise Lactobacillus crispatus.

10. A method for modifying an individual's gut-brain axis to provide neurocognitive protection, comprising,

providing an individual human being with a population of beneficial bacteria selected from the group consisting of at least two bacteria selected from the group consisting of Blautia, Coprococcus, Faecalibacterium prausnitzii; Nitrosomonas eutropha, Roseburia intestinalis, Lactobacillus paracasei , and Lactobacillus plantarum;

administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

wherein the bacterial formulation generates an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists and thereby reduce inflammation in the individual's gut; wherein at least some bacteria in the bacterial formulation have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to enhance the generation of a tryptophan metabolite, and wherein the beneficial bacteria are encapsulated in a frangible enclosure, increasing the populations of at least two of the following in the individual's gut microbiome: Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp. and Veillonella , and inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.

11. The method as set forth in claim 10 , further comprising reducing bacteria in the gut of the individual selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

12. The method as set forth in claim 10 , and inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

13. The method as set forth in claim 10 , further comprising administering Bifidobacterium breve and B. longum in an amount sufficient to achieve at least one of the following: decrease the severity of diarrhea; and reduce the symptoms of celiac disease.

14. A method for modifying an individual's gut-brain axis to provide neurocognitive protection, comprising,

providing an individual human being with a population of beneficial bacteria selectedfrom the group consisting of at least two bacteria selected from the group consisting of; Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum, Roseburia intestinalis, Coprococcus spp., Lactobacillus paracasei, Nitrosomonas eutropha , Blautia, Lactobacillus plantarum and Veillonella,

administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and

wherein the bacterial formulation generates an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists and thereby reduce inflammation in the individual's gut; wherein the beneficial bacteria are encapsulated in a frangible enclosure.

15. The method as set forth in claim 14 , wherein a secretion of glucagon-like peptide-1 (GLP-1) is stimulated in the individual due to the production of small chain fatty acids by the beneficial bacteria.

16. The method as set forth in claim 14 , wherein the beneficial bacteria are selected from the group consisting of bacterial species able to produce small chain fatty acids.

17. The method as set forth in claim 14 , further comprising inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.

18. The method as set forth in claim 14 , further comprising reducing bacteria in the gut of the individual selected from the group consisting of Pediococcus, Streptococcus, Enterococcus , and Leuconostoc bacteria.

19. The method as set forth in claim 14 , and inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.

20. The method as set forth in claim 14 , further comprising administering Bifidobacterium breve and B. longum in an amount sufficient to achieve at least one of the following: decrease the severity of diarrhea; and reduce the symptoms of celiac disease.

Assignments (2)

Continuity (65)

References Cited (400)